SRRA News and Press, Sierra Oncology Inc. From 03/17/22

Sierra Oncology Inc. (NASDAQ:SRRA) traded at a new 52-week high today of $36.77. Approximately 2.9 million shares have changed hands today, as compared to an average 30-day volume of 339,000 shares. Sierra Oncology Inc. share prices have moved between a 52-week high of $36.77 and a 52-we...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32 nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022. P...

Sierra Oncology press release (NASDAQ:SRRA): Q4 Non-GAAP EPS of -$1.44.  Cash and cash equivalents totaled $104.7 million as of December 31, 2021, compared to $104.1 million as of December 31, 2020. For further details see: Sierra Oncology Non-GAAP EPS of -$1.44

– Planned Q2 2022 NDA submission following positive topline data from MOMENTUM clinical trial of momelotinib in symptomatic and anemic myelofibrosis patients – – Financial position significantly strengthened – Sierra Oncology, Inc. (NASDAQ...

We are initiating with CTI BioPharma with a buy rating with a TP of USD 7.6 if pacritinib is approved. We opine that CTI BioPharma's current set-up represents an attractive risk-reward scenario with ~50% potential downside (around cash value of $1/share) and ~320% potential upside (bu...

Sierra Oncology Inc. (NASDAQ:SRRA) traded at a new 52-week high today of $32.09. Approximately 2.9 million shares have changed hands today, as compared to an average 30-day volume of 2.2 million shares. There is potential upside of 5.9% for shares of Sierra Oncology Inc. based on a curre...

Sierra Oncology (NASDAQ:SRRA) said the underwriters of its previously announced public offering exercised in full their option to buy an additional 750K common shares at $27 per share. With this exercise, the gross proceeds to Sierra were ~$155.3M. Sierra intends to use the net proceeds ...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 add...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 4 th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, ...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its common stock at a price to the public...